<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05029141</url>
  </required_header>
  <id_info>
    <org_study_id>SZCAHAG</org_study_id>
    <nct_id>NCT05029141</nct_id>
  </id_info>
  <brief_title>New Double Epigenetic Regimen in the Treatment of Relapsed or Refractory Acute Myeloid Leukemia</brief_title>
  <official_title>A Multi-center, Randomized Clinical Trial of Chidamide Combined With Azacytidine and the HAG Regimen in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The First Affiliated Hospital of Soochow University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ruijin Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West China Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fujian Medical University Union Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The First Hospital of Jilin University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Anhui Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Qilu Hospital of Shandong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The Affiliated Cancer Hospital of Zhengzhou University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Shandong Provincial Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>First Affiliated Hospital of Harbin Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Xinqiao Hospital of Chongqing</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>The First Affiliated Hospital of Soochow University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is to investigate the therapeutic efficacy and side effect of chidamide,&#xD;
      azacitidine combined with priming HAG regimen for relapsed or refractroy acute myeloid&#xD;
      leukemia&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>The overall response (completed remission without minimal residual disease, completed remission with incomplete blood count recovery, morphologic leukemia-free state and partial remission) rate achieved after one or two courses(28 days) induction therapy by CAHAG regimen.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission without minimal residual disease (CR with MRD-)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>If studied pretreatment, CR with negativity for a genetic marker by RT-qPCR, or CR with negativity by MFC</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Complete remission with incomplete hematologic recovery (CRi)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>All CR criteria except for residual neutropenia (,1.0*10E9/L [1000/uL]) or thrombocytopenia (&lt;100*10E9/L [100 000/uL])</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Morphologic leukemia-free state (MLFS)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Bone marrow blasts ,5%; absence of blasts with Auer rods; absence of extramedullary disease; no hematologic recovery required</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Partial remission (PR)</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>All hematologic criteria of CR; decrease of bone marrow blast percentage to 5% to 25%; and decrease of pretreatment bone marrow blast percentage by at least 50%.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>1 year</time_frame>
    <description>It is measured the time from initial response to subsequent disease progression or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>1 year</time_frame>
    <description>It is measured from the time of entry into this trial to the date of death from any cause; patients not known to have died at last follow-up are censored on the date they were last known to be alive.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>1 year</time_frame>
    <description>It is measured from the time from randomization to progression or death.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse reactions in hematology</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Record of adverse events in hematological system during and after CAHAG regimen induction (agranulocytosis days, PLT/RBC transfusion units).</description>
  </other_outcome>
  <other_outcome>
    <measure>Nonhematological adverse reactions</measure>
    <time_frame>At the end of Cycle 1 (each cycle is 28 days)</time_frame>
    <description>Record of adverse events in other organs or systmes during and after CAHAG regimen induction (infection and organ injury).</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">219</enrollment>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Refractory Acute Leukemia</condition>
  <condition>Relapsed Adult AML</condition>
  <arm_group>
    <arm_group_label>Chidamide+AZA+HHT+AraC+G-CSF group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The patients are randomized into the group. Patients whose last induction failure regimen is a demethylated agent combined with priming regimen enter the experimental group directly.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo+AZA+HHT+AraC+G-CSF group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The patients are randomized into the group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CAHAG regimen</intervention_name>
    <description>Chidamide 30mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC &gt; 20×10E9/L, G-CSF paused).&#xD;
One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE&lt;1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.</description>
    <arm_group_label>Chidamide+AZA+HHT+AraC+G-CSF group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo regimen</intervention_name>
    <description>Chidamide 0mg orally twice every week for 2 weeks on days 1, 4, 8, 11, azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9) and HAG regimen (cytarabine, 10 mg/m2 subcutaneously every 12 h on days 3-16; homoharringtonine, 1mg/m2 intravenously every day on days 3-16; and concurrent granulocyte colony-stimulating factor, 200mg/m2/day subcutaneously daily from days 2 to neutral granulocyte recovery. (when WBC &gt; 20×10E9/L, G-CSF paused).&#xD;
One treatment cycle for 28 days, a total of 2 cycles. If the bone marrow assessment is MLFS on the 28th day in the first cycle, the second cycle of treatment will be started after NE&lt;1.0×10E9/L; if the delay exceeds 2 weeks, the patient needs to withdraw from the trial.</description>
    <arm_group_label>Placebo+AZA+HHT+AraC+G-CSF group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults aged ≥ 18 and ≤ 70 years&#xD;
&#xD;
          -  Patients diagnosed with AML according to 2016 WHO myeloid malignant disease diagnosis&#xD;
             standard (Non-APL)&#xD;
&#xD;
          -  Patients with AML must meet one of the following criteria, A or B:&#xD;
&#xD;
        A: Refractory AML disease was defined as follows: (1) failure to attain CR following&#xD;
        exposure to at least 2 courses of standard or intensive induction therapy; or (2) bone&#xD;
        marrow leukemia cell decline index (BMCDI) &lt; 50% and &gt; 20% after 1 course of standard or&#xD;
        intensive induction therapy. B: Relapsed AML disease was defined as follows: (1)&#xD;
        reappearance of leukemic blasts in the peripheral blood after CR; or (2) detection of ≥ 5%&#xD;
        blasts in the BM not attributable to another cause (e.g., BM regeneration after&#xD;
        consolidation therapy); or (3) extramedullary relapse.&#xD;
&#xD;
          -  ECOG performance status score less than 3&#xD;
&#xD;
          -  Expected survival time ˃ 3 months&#xD;
&#xD;
          -  Patients without serious heart, lung, liver, or kidney disease&#xD;
&#xD;
          -  Ability to understand and voluntarily provide informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are allergic to the study drug or drugs with similar chemical structures&#xD;
&#xD;
          -  Pregnant or lactating women, and women of childbearing age who do not want to practice&#xD;
             effective methods of contraception&#xD;
&#xD;
          -  Active infection&#xD;
&#xD;
          -  Active bleeding&#xD;
&#xD;
          -  Patients with new thrombosis, embolism, cerebral hemorrhage, or other diseases or a&#xD;
             medical history within one year before enrollment&#xD;
&#xD;
          -  Patients with mental disorders or other conditions whereby informed consent cannot be&#xD;
             obtained and where the requirements of the study treatment and procedures cannot be&#xD;
             met&#xD;
&#xD;
          -  Liver function abnormalities (total bilirubin &gt; 1.5 times the upper limit of the&#xD;
             normal range, ALT/AST &gt; 2.5 times the upper limit of the normal range or patients with&#xD;
             liver involvement whose ALT/AST &gt; 1.5 times the upper limit of the normal range), or&#xD;
             renal anomalies (serum creatinine &gt; 1.5 times the upper limit of the normal value)&#xD;
&#xD;
          -  Patients with a history of clinically significant QTc interval prolongation (male &gt;&#xD;
             450 ms; female &gt; 470 ms), ventricular heart tachycardia and atrial fibrillation,&#xD;
             II-degree heart block, myocardial infarction attack within one year before enrollment,&#xD;
             and congestive heart failure, and patients with coronary heart disease who have&#xD;
             clinical symptoms and requiring drug treatment&#xD;
&#xD;
          -  Surgery on the main organs within the past six weeks&#xD;
&#xD;
          -  Drug abuse or long-term alcohol abuse that would affect the evaluation results&#xD;
&#xD;
          -  Patients who have received organ transplants (excepting bone marrow transplantation)&#xD;
&#xD;
          -  Patients not suitable for the study according to the investigator's assessment&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>69 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Sheng-Li Xue, M. D.</last_name>
    <phone>008651267781139</phone>
    <email>slxue@suda.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>The First Affliated Hospital of Soochow University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sheng-Li Xue, M.D.</last_name>
      <phone>+86 512 6778 1139</phone>
      <email>slxue@suda.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>August 16, 2021</study_first_submitted>
  <study_first_submitted_qc>August 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 31, 2021</study_first_posted>
  <last_update_submitted>October 10, 2021</last_update_submitted>
  <last_update_submitted_qc>October 10, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The First Affiliated Hospital of Soochow University</investigator_affiliation>
    <investigator_full_name>Sheng-Li Xue, MD</investigator_full_name>
    <investigator_title>accociate professor</investigator_title>
  </responsible_party>
  <keyword>chidamide</keyword>
  <keyword>Azacitidine</keyword>
  <keyword>priming regimen</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

